{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:58:32Z","timestamp":1793854712266,"version":"4.6.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["NRF-2017R1A5A1070259"],"award-info":[{"award-number":["NRF-2017R1A5A1070259"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["NRF-2016M3A9B5941836"],"award-info":[{"award-number":["NRF-2016M3A9B5941836"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["NRF-2016M3A9B6903426"],"award-info":[{"award-number":["NRF-2016M3A9B6903426"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["NRF-2018R1A2A1A05020064"],"award-info":[{"award-number":["NRF-2018R1A2A1A05020064"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["NRF-2017M3A9F5029655"],"award-info":[{"award-number":["NRF-2017M3A9F5029655"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.biomaterials.2018.08.007","type":"journal-article","created":{"date-parts":[[2018,8,6]],"date-time":"2018-08-06T23:29:23Z","timestamp":1533598163000},"page":"35-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Metronomic oral doxorubicin in combination of Chk1 inhibitor MK-8776 for p53-deficient breast cancer treatment"],"prefix":"10.1016","volume":"182","author":[{"given":"Seung Woo","family":"Chung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui Chul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seho","family":"Kweon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanul","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Uk","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Foyez","family":"Mahmud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Won","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo-Chan","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Yoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngro","family":"Byun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.biomaterials.2018.08.007_bib1","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1172\/JCI9872","article-title":"Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice","volume":"105","author":"Hanahan","year":"2000","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.biomaterials.2018.08.007_bib2","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/nrc1650","article-title":"Repopulation of cancer cells during therapy: an important cause of treatment failure","volume":"5","author":"Kim","year":"2005","journal-title":"Nat. Rev. Canc."},{"issue":"7","key":"10.1016\/j.biomaterials.2018.08.007_bib3","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrclinonc.2014.89","article-title":"Metronomics: towards personalized chemotherapy?","volume":"11","author":"Andre","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biomaterials.2018.08.007_bib4","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.canlet.2016.12.041","article-title":"Metronomics in the neoadjuvant and adjuvant treatment of breast cancer","volume":"400","author":"Munzone","year":"2017","journal-title":"Canc. Lett."},{"key":"10.1016\/j.biomaterials.2018.08.007_bib5","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.canlet.2016.12.019","article-title":"Metronomic chemotherapy for advanced breast cancer patients","volume":"400","author":"Cazzaniga","year":"2017","journal-title":"Canc. Lett."},{"issue":"11","key":"10.1016\/j.biomaterials.2018.08.007_bib6","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nrclinonc.2015.131","article-title":"Clinical overview of metronomic chemotherapy in breast cancer","volume":"12","author":"Munzone","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7015","key":"10.1016\/j.biomaterials.2018.08.007_bib7","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nature03097","article-title":"Cell-cycle checkpoints and cancer","volume":"432","author":"Kastan","year":"2004","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.biomaterials.2018.08.007_bib8","first-page":"31","article-title":"The protein kinase C inhibitor Go6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle checkpoints","volume":"63","author":"Kohn","year":"2003","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.biomaterials.2018.08.007_bib9","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1002\/ijc.22198","article-title":"Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics","volume":"119","author":"Chen","year":"2006","journal-title":"Int. J. Canc."},{"issue":"4","key":"10.1016\/j.biomaterials.2018.08.007_bib10","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1172\/JCI58765","article-title":"Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models","volume":"122","author":"Ma","year":"2012","journal-title":"J. Clin. Invest."},{"issue":"18","key":"10.1016\/j.biomaterials.2018.08.007_bib11","doi-asserted-by":"crossref","first-page":"8493","DOI":"10.1073\/pnas.92.18.8493","article-title":"p53 controls both the G2\/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts","volume":"92","author":"Agarwal","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"6","key":"10.1016\/j.biomaterials.2018.08.007_bib12","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/humu.20495","article-title":"Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database","volume":"28","author":"Petitjean","year":"2007","journal-title":"Hum. Mutat."},{"issue":"1","key":"10.1016\/j.biomaterials.2018.08.007_bib13","first-page":"7","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"Ca - Cancer J. Clin."},{"issue":"21","key":"10.1016\/j.biomaterials.2018.08.007_bib14","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1001\/jama.295.21.2492","article-title":"Race, breast cancer subtypes, and survival in the carolina breast cancer study","volume":"295","author":"Carey","year":"2006","journal-title":"J. Am. Med. Assoc."},{"issue":"12","key":"10.1016\/j.biomaterials.2018.08.007_bib15","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1038\/sj.bjc.6690628","article-title":"Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis","volume":"80","author":"Pharoah","year":"1999","journal-title":"Br. J. Canc."},{"issue":"24","key":"10.1016\/j.biomaterials.2018.08.007_bib16","doi-asserted-by":"crossref","first-page":"6723","DOI":"10.1158\/1078-0432.CCR-12-2442","article-title":"Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias","volume":"18","author":"Karp","year":"2012","journal-title":"Clin. Canc. Res."},{"issue":"2","key":"10.1016\/j.biomaterials.2018.08.007_bib17","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1158\/1535-7163.MCT-11-0406","article-title":"Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites","volume":"11","author":"Montano","year":"2012","journal-title":"Mol. Canc. Therapeut."},{"issue":"9","key":"10.1016\/j.biomaterials.2018.08.007_bib18","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1200\/JCO.2014.57.5027","article-title":"Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors","volume":"33","author":"Daud","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.biomaterials.2018.08.007_bib19","doi-asserted-by":"crossref","first-page":"6543","DOI":"10.1016\/j.biomaterials.2014.04.050","article-title":"Oral delivery of a potent anti-angiogenic heparin conjugate by chemical conjugation and physical complexation using deoxycholic acid","volume":"35","author":"Alam","year":"2014","journal-title":"Biomaterials"},{"issue":"6","key":"10.1016\/j.biomaterials.2018.08.007_bib20","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1021\/mp500626a","article-title":"Absorption mechanism of a physical complex of monomeric insulin and deoxycholyl-l-lysyl-methylester in the small intestine","volume":"12","author":"Mahmud","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biomaterials.2018.08.007_bib21","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jconrel.2017.01.020","article-title":"Metronomic chemotherapy using orally active carboplatin\/deoxycholate complex to maintain drug concentration within a tolerable range for effective cancer management","volume":"249","author":"Mahmud","year":"2017","journal-title":"J. Contr. Release"},{"issue":"9","key":"10.1016\/j.biomaterials.2018.08.007_bib22","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1038\/nprot.2007.303","article-title":"Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers","volume":"2","author":"Hubatsch","year":"2007","journal-title":"Nat. Protoc."},{"issue":"2","key":"10.1016\/j.biomaterials.2018.08.007_bib23","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0378-4347(98)00475-7","article-title":"High-performance liquid chromatographic validated assay of doxorubicin in rat plasma and tissues","volume":"721","author":"Alvarez-Cedron","year":"1999","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"issue":"1","key":"10.1016\/j.biomaterials.2018.08.007_bib24","article-title":"Autophagy inhibition contributes to the synergistic interaction between EGCG and doxorubicin to kill the hepatoma Hep3B cells","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.biomaterials.2018.08.007_bib25","doi-asserted-by":"crossref","first-page":"21010","DOI":"10.1038\/srep21010","article-title":"\u03b2-elemene sensitizes hepatocellular carcinoma cells to oxaliplatin by preventing oxaliplatin-induced degradation of copper transporter 1","volume":"6","author":"Li","year":"2016","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.biomaterials.2018.08.007_bib26","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.biomaterials.2018.08.007_bib27","first-page":"766","article-title":"Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer, Int","volume":"78","author":"Gazdar","year":"1998","journal-title":"J. Canc."},{"issue":"19","key":"10.1016\/j.biomaterials.2018.08.007_bib28","first-page":"284","article-title":"Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple negative breast cancer: a phase III study","volume":"3","author":"Nasr","year":"2015","journal-title":"Ann. Transl. Med."},{"issue":"1","key":"10.1016\/j.biomaterials.2018.08.007_bib29","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1186\/s12885-016-2823-y","volume":"16","author":"Rochlitz","year":"2016","journal-title":"BMC Canc."},{"key":"10.1016\/j.biomaterials.2018.08.007_bib30","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.canlet.2017.01.027","article-title":"Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: a phase II trial","volume":"400","author":"Montagna","year":"2017","journal-title":"Canc. Lett."},{"issue":"7","key":"10.1016\/j.biomaterials.2018.08.007_bib31","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3109\/00498254.2012.751140","article-title":"The limited intestinal absorption via paracellular pathway is responsible for the low oral bioavailability of doxorubicin","volume":"43","author":"Kim","year":"2013","journal-title":"Xenobiotica"},{"issue":"11","key":"10.1016\/j.biomaterials.2018.08.007_bib32","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1158\/1535-7163.MCT-13-0404","article-title":"Identification of preferred chemotherapeutics for combining with a CHK1 inhibitor","volume":"12","author":"Xiao","year":"2013","journal-title":"Mol. Canc. Therapeut."},{"issue":"51","key":"10.1016\/j.biomaterials.2018.08.007_bib33","doi-asserted-by":"crossref","first-page":"53272","DOI":"10.1074\/jbc.M406879200","article-title":"Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species","volume":"279","author":"Kurz","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.biomaterials.2018.08.007_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yexcr.2004.10.016","article-title":"The relative contribution of CHK1 and CHK2 to Adriamycin-induced checkpoint","volume":"304","author":"Ho","year":"2005","journal-title":"Exp. Cell Res."},{"issue":"2","key":"10.1016\/j.biomaterials.2018.08.007_bib35","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10637-013-0036-7","article-title":"Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor","volume":"32","author":"King","year":"2014","journal-title":"Invest. New Drugs"},{"issue":"5","key":"10.1016\/j.biomaterials.2018.08.007_bib36","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.cellsig.2015.01.020","article-title":"Chk1 and Wee 1 control genotoxic-stress induced G2-M arrest in melanoma cells","volume":"27","author":"Vera","year":"2015","journal-title":"Cell. Signal."},{"issue":"10","key":"10.1016\/j.biomaterials.2018.08.007_bib37","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.neo.2017.08.002","article-title":"Chk1 inhibitor SCH900776 effectively potentiates the cytotoxic effects of platinum-based chemotherapeutic drugs in human colon cancer cells","volume":"19","author":"Herudkova","year":"2017","journal-title":"Neoplasia"},{"issue":"44","key":"10.1016\/j.biomaterials.2018.08.007_bib38","doi-asserted-by":"crossref","first-page":"71660","DOI":"10.18632\/oncotarget.12311","article-title":"MK-8776, a novel chk1 kinase inhibitor, radiosensitizes p53-defective human tumor cells","volume":"7","author":"Bridges","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.biomaterials.2018.08.007_bib39","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.lungcan.2013.09.010","article-title":"CHK1 levels correlate with sensitization to pemetrexed by CHK1 inhibitors in non-small cell lung cancer cells","volume":"82","author":"Grabauskiene","year":"2013","journal-title":"Lung Canc."},{"issue":"46","key":"10.1016\/j.biomaterials.2018.08.007_bib40","doi-asserted-by":"crossref","first-page":"6149","DOI":"10.1038\/onc.2010.343","article-title":"Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents","volume":"29","author":"Zenvirt","year":"2010","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.biomaterials.2018.08.007_bib41","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/jnci\/53.3.661","article-title":"Breast tumor cell lines from pleural effusions","volume":"53","author":"Cailleau","year":"1974","journal-title":"J. Natl. Cancer Inst."},{"issue":"6","key":"10.1016\/j.biomaterials.2018.08.007_bib42","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1535-6108(03)00132-6","article-title":"A multigenic program mediating breast cancer metastasis to bone","volume":"3","author":"Kang","year":"2003","journal-title":"Canc. Cell"},{"issue":"1","key":"10.1016\/j.biomaterials.2018.08.007_bib43","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1172\/JCI22320","article-title":"Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors","volume":"115","author":"Minn","year":"2005","journal-title":"J. Clin. Invest."},{"issue":"13","key":"10.1016\/j.biomaterials.2018.08.007_bib44","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1056\/NEJM199809243391307","article-title":"Doxorubicin-induced cardiomyopathy","volume":"339","author":"Singal","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biomaterials.2018.08.007_bib45","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.tox.2004.12.003","article-title":"Doxorubicin hepatotoxicity and hepatic free radical metabolism in rats. The effects of vitamin E and catechin","volume":"209","author":"Kalender","year":"2005","journal-title":"Toxicology"}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961218305611?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961218305611?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T16:35:36Z","timestamp":1758904536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961218305611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":45,"alternative-id":["S0142961218305611"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2018.08.007","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metronomic oral doxorubicin in combination of Chk1 inhibitor MK-8776 for p53-deficient breast cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2018.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}